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The existence of a tissue renin–angiotensin (RAS) system
independent of the circulating RAS has prompted the search
for cellular binding sites for angiotensinogen and for renin in
order to explain their tissue uptake. Two receptors that bind
with similar affinity mature renin and prorenin were
identified, the mannose-6-phosphate receptor (M6P-R) and
a specific receptor. The M6P-R is a clearance receptor that
binds exclusively the glycosylated forms of renin and
prorenin. Binding of renin and prorenin to the M6P-R is
followed by internalization and degradation, and the
intracellular proteolysis of prorenin in mature renin did not
provoke any generation of intracellular angiotensins. In
contrast to the M6P-R, (pro)renin bound to the specific
receptor was not degraded. Instead, receptor-bound renin
showed increased catalytic activity, and receptor-bound
prorenin exhibited full catalytic activity. This ‘gain of activity’
was explained by a conformational change of the (pro)renin
molecule upon binding. Furthermore, (pro)renin binding
provoked a rapid activation of the mitogen-activated protein
kinases p44/p42, indicating that the receptor has mediated
specific, angiotensin II-independent effects of (pro)renin. This
receptor represents an elegant concept to explain the
existence of active prorenin in vivo, and it provides a
pathological role for prorenin in situations with paradoxical
low renin and high prorenin concentrations such as in
diabetes. Experimental models of rats overexpressing the
receptor either in vascular smooth muscle cells and
developing high blood pressure or with ubiquitous
expression associated with glomerulosclerosis and
proteinuria confirm a role for the receptor in cardiovascular
and renal diseases.
Kidney International (2006) 69, 1503–1506. doi:10.1038/sj.ki.5000265;
published online 1 March 2006
KEYWORDS: renin–angiotensin system; hypertension; glomerulosclerosis;
cardiovascular disease; diabetic nephropathy
The renin–angiotensin system (RAS) is classically described
as a circulating system with a single end point, the generation
of angiotensin II (Ang II) that plays major role in the control
of blood pressure and fluid, and salt balance through binding
to its receptors. But the activation of the RAS is also involved
in physiological processes such as development, learning and
memory, in tissue growth, and in pathological diseases such
as inflammation, in macro- and micro-vascular hypertrophy
(atherosclerosis and diabetic retinopathy) and vascular
remodeling (including in tumors), fibrosis and obesity, all
processes in relation with a tissue RAS. The existence of a
local generation of angiotensins independent of circulating
angiotensins is now admitted, and the prerequisite is the
presence of renin in tissue, but except in eye, adrenal, testis,
ovaries, and brain where prorenin synthesis was shown, renin
and prorenin in tissues accumulate in the interstitial fluid by
diffusion or are taken up by binding sites and/or receptors.1,2
Renin is an aspartyl-protease that exists in two forms,
the proenzyme prorenin and mature renin. Prorenin is
transformed into mature renin by cleavage of the 43 amino
acids of the pro-segment. Mature renin in the circulation
originates from the myo-epithelioid cells of the juxta-
glomerular apparatus that are responsible for the synthesis
and the processing of prorenin into mature renin and the
release of renin in the circulation. Prorenin, although
synthesized by a restricted number of tissues, represents up
to 90% of total plasma renin in normal subjects. This excess
of prorenin that cannot be activated in the circulation has
intrigued for a long time, and the hypothesis of a functional
role of prorenin was suggested. The discovery of receptors for
renin and prorenin has revived the interest for a physiological
role of prorenin and for (pro)renin specific functions
independent of Ang II generation.
Several renin binding proteins (RnBPs) were described, on
cell membranes prepared from rat tissues with no further
characterization,3 and in the intracellular compartment.
The protein identified in the intracellular compartment was
called renin binding protein was shown to be identical to the
enzyme N-acyl-D-glucosamine 2 epimerase. Although renin
binding protein could inhibit renin activity in vitro, mice
RnBP/ have normal plasma renin activity and normal
blood pressure, making unlikely a role for renin binding
protein in the control of renin activity in vivo.4
To date, two receptors have been identified and charac-
terized, the mannose-6-phosphate receptor (M6P-R) and the
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specific receptor, and a third receptor on rat cardiomyocytes
was described.
THE RENIN AND PRORENIN RECEPTORS
A receptor for unglycosylated prorenin on rat adult
cardiomyocytes
Using rats transgenic for the mouse ren-2d renin gene (coding
for unglycosylated prorenin) and with an inducible expres-
sion restricted to the liver, Peters et al.5 have shown an
increased synthesis of ren-2d renin associated with high levels
of ren-2d prorenin in plasma and, surprisingly, also within
cardiac cells. In addition, they showed that the unglycosylated
ren-2d prorenin was able to bind in vitro to rat cardio-
myocytes and that bound-prorenin was internalized, whereas
mature ren-2d renin was weakly bound and internalized.
Prorenin internalization was associated with an increased
intrinsic catalytic activity and, remarkably, with intracellular
Ang I and Ang II generation. Unfortunately, this receptor was
not further characterized.
The M6P-R
The M6P-R, also called insulin-like growth factor II receptor,
is an ubiquitous receptor that was shown to bind renin and
prorenin on neonatal rat cardiomyocytes6 and on human
endothelial cells7 with an affinity of about 1 nM. In contrast
to the receptor for unglycosylated (pro)renin described by
Peters et al., the M6P-R binds equally well renin and prorenin
but exclusively the M6P containing (pro)renin. The M6P-R/
(pro)renin complex is then internalized, prorenin activated
in mature renin by proteolysis and renin was subsequently
degraded. Intracellular prorenin activation did not result in
intra or extracellular angiotensin generation. Therefore, this
receptor appears to be most likely a clearance receptor.
The specific receptor
A receptor of mature renin was first identified on human
mesangial cells in culture. Renin binding to the receptor did
not involve the active site and binding induced an increase of
[3H] thymidine incorporation and of plasminogen activator
inhibitor-1 synthesis.8 This receptor is a 350-amino-acid
protein with a single trans-membrane domain cloned by
screening a human adult kidney expression library with
labeled renin. This receptor also binds prorenin, the inactive
precursor of renin. Receptor-bound renin exhibited increased
catalytic activity ( 5) and receptor-bound prorenin ex-
hibited full enzymatic activity comparable to that of mature
renin in solution. This ‘gain of activity’ of renin and prorenin
was explained by a conformational change induced by the
binding. In addition, binding of (pro)renin to the receptor
triggered an intracellular signaling and the phosphorylation
of the mitogen-activated protein kinases p44(ERK1)/
p42(ERK2).
Immunofluorescence studies performed on frozen tissues
have initially localized the receptor in glomerular mesangial
cells and in vascular smooth muscle cells of renal cortical
arteries and coronary arteries.9
POTENTIAL SIGNIFICANCE OF THE SPECIFIC (PRO)RENIN
RECEPTOR
The specific receptor provides a functional role for prorenin
In plasma, prorenin represents 70–90% of total circulating
renin in normal subjects, and up to 95% of in diabetic
patients.10,11 Prorenin is catalytically inactive when its pro-
segment covers the cleft containing the active site. Prorenin
can acquire a catalytic activity after transforming in mature
renin by cleavage of the prosegment (an irreversible process
known as ‘proteolytic activation’) or by physical means
such as low pH or cold that unfold the propeptide from
the enzymatic cleft (‘non-proteolytic’ activation that can
be reversed by increasing the pH or the temperature). The
physiological proteolytic activation or processing of renin is
probably due to a proconvertase in the renin-producing cells
of the juxta-glomerular apparatus. In vitro, limited proteo-
lysis by kallikrein, plasmin, and trypsin can also remove the
propeptide to yield the mature renin and nonproteolytic
activation of prorenin can also be observed when prorenin is
bound to an antibody against a called ‘handle’ region of the
pro-segment12 triggering a conformational change of the
molecule provoking the opening of the access to the catalytic
site of prorenin. Since in vivo, no antibody to the handle
region exists, the authors hypothesized that renin binding
sites, in particular the renin receptor could play this role
especially in situations with high prorenin concentrations
like in diabetes. Subsequently, Ichihara et al.13 showed that
the infusion of a decoy peptide corresponding to the handle
region of prorenin in streptozotocin-induced diabetic rats
could completely prevent diabetic nephropathy assessed on
morphological and functional data and could also normalize
the kidney content of Ang II. Furthermore, the decoy peptide
did not modify the plasma content of Ang I and Ang II in
diabetic rats nor did it affect tissue Ang I and Ang II in
control rats. This study provides the first evidence that
prorenin can contribute to Ang I and Ang II formation in the
kidney of diabetic rat, and it supports experimental data
showing that in vivo prorenin was catalytically active.14
If the pathogenic role of the receptor-activated prorenin
in diabetic nephropathy can be confirmed, for example, by
using renin receptor-deficient animals, then these results
would have major therapeutic consequences, implying that
an inhibitor of prorenin and renin active site or a compound
able to inhibit both (pro)renin binding and activity would be
beneficial in diabetic nephropathy.
Signaling of the renin receptor via ERK1/2 activation is
important for cell function in the central nervous system
In the central nervous system, the role of the RAS is involved
in a wide variety of functions, including the control of cell
growth and death, the neuro-endocrine regulation, cognitive
properties, the modulation of cardiovascular functions such
as autonomic activity, salt intake, and drinking. We have
recently found a specific role for the renin receptor in
cognitive functions and brain development related to the
mutation in the renin receptor gene (ATP6AP2). The patients
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suffered X-linked mental retardation and epilepsy, and no
apparent cardiovascular or renal dysfunction. This mutation
resulted in the deletion of exon 4 in 50% of renin receptor
mRNA and functional studies showed that, although the
mutated receptor could bind renin and increase renin cata-
lytic activity as described for wild-type receptor, renin bind-
ing did not activate the mitogen-activated protein kinases
ERK1/2.15 The reason why the central nervous system is more
sensitive to the lack of renin receptor is not known yet, but
our findings suggest that activation of the ERK1/2 system via
the renin receptor system is important in brain development
and to maintain normal neurological functions. Its impair-
ment can apparently not be compensated by other extra-
cellular stimuli as for cardiac, vascular, and renal tissues.
The renin receptor may be important for cell metabolism
A 8.9 kDa fragment of the renin receptor called M8.9 and
corresponding to the cytoplasmic, the trans-membrane
and part of the extracellular domain was described to co-
precipitate with the vacuolar proton-ATPase in chromaffin
granules.16 Since there is only one gene for the renin receptor
and the M8.9 protein, it is likely that both proteins derive
from the same transcript, but the mechanisms leading to
the generation of the 8.9 kDa fragment are not known yet.
In silico research showed that the renin receptor protein
is highly homologous in human, mouse, and rat, as well as in
chicken, fish, Xenopus, and C. elegans especially the segment
associated with the vacuolar proton-ATPase,17 suggesting an
important conserved function for the renin receptor. Indeed,
the ablation of the renin receptor gene in embryonic stem
cells is not compatible with their participation in embryonic
development after injection into blastocysts (C Burckle and
M Bader, personal communication) and renin receptor gene
appears to be essential for early zebrafish development since
its inactivation is lethal before the end of the embryo-
genesis.18 Therefore, it is likely that the renin receptor should
possess two types of function, one function as a plasma
membrane protein acting as a receptor for prorenin and one
function independent of the RAS, and related to the M8-9
fragment associated with the vacuolar proton-ATPase.
Rats overexpressing the renin receptor have cardiovascular
and renal dysfunctions
To study the role of the renin receptor in vivo, rats
overexpressing the receptor were generated in which the
human receptor gene was expressed in smooth muscle tissue
under the control of the mouse smooth muscle myosin heavy
chain gene or under the control of the cytomegalovirus
promoter. Overexpression of the human receptor under the
control of smooth muscle myosin heavy chain gene induced a
strong expression in vascular smooth-muscle cells, and the
rats developed at the age of 6 months, a cardiovascular
phenotype with an increase of systolic blood pressure and
of heart rate as compared to their littermates, and these
alterations progressively worsened with aging. Although
kidney function and plasma renin were normal in transgenic
rats, the plasma aldosterone and in aldosterone/renin ratio
were higher in transgenic animals. The mechanism of the
increased aldosteronemia is not fully understood, but it could
underlie the cardiovascular phenotype of these rats.19 On the
other hand, overexpression of human receptor under the
control of cytomegalovirus promoter induced an ubiquitous
but very modest increase of receptor expression. These rats
have no increased blood pressure or kidney Ang II content;
however, they had increased urinary protein excretion
compared to control rats and significant glomerulosclerosis
at the age of 28 weeks (Kaneshiro Y et al., Transgenic Rats
Overexpressing the Human Prorenin Receptor Gene Develop
Glomerular Sclerosis without Hypertension or Diabetes. J Am
Soc Nephrol 2005; 16: 74A–75A). Whether or not glomerulo-
sclerosis could be linked to ERK1/2 activation by the renin
receptor remains to be determined. However, the role of
(pro)renin receptor activation in glomerular fibrosis is
supported by the excellent work of Huang et al., who showed
that activation of the (pro)renin receptor increased TGFb
synthesis by human and rat mesangial cells. This upregula-
tion of TGFb was responsible in part of the increased
synthesis of plasminogen activator inhibitor-1 and fibrotic
matrix components such as fibronectin and collagen I. Using
the siRNA technique, these authors unequivocally demons-
trated that the increase of TGFb was due to activation of the
renin receptor.20 Finally, the data from transgenic rats
confirm that the specific renin receptor plays a role in the
control of cardiovascular and renal physiopathology, but the
challenge now is to decipher the mechanisms underlying the
receptor functions.
SUMMARY AND PERSPECTIVES
Two major facts have emerged from the studies on the
(pro)renin receptors. First, the receptors binds not only
mature renin but also prorenin resulting in prorenin
activation. Whether prorenin is proteolytically activated
within the cell or nonproteolytically activated at the cell
surface, its activation is associated with angiotensins genera-
tion providing the first demonstration of a physiological role
of prorenin. Second, experimental data on transgenic rats
confirm a link between the overexpression of the receptor
and cardiovascular and renal dysfunctions possibly involving
direct activation of the receptor by (pro)renin. It would be of
interest to know now if the renin inhibitors clinically
available soon will be able to interfere with receptor-bound
renin and prorenin activity, and with receptor activation or
expression, and to compare them with angiotensin convert-
ing enzyme inhibitors and angiotensin receptor blockers for
their tissue-protective effects in view of therapeutic use.
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